作者:Joshi, Rupal J.、Dholariya, Monil P.、Chothani, Savankumar R.、Chamakiya, Chirag A.、Varu, Hardik L.、Karmur, Manisha B.、Maliwal, Deepika、Pissurlenkar, Raghuvir R.S.、Bapodra, Atul H.、Patel, Anilkumar S.、Kapuriya, Naval P.
DOI:10.1016/j.molstruc.2024.138570
日期:——
Benzo[b]thiophene has been implicated as molecular framework in the drug discovery against broad spectrum of biological targets. In the antidiabetic drug regime, benzo[b]thiophene based SGLT2 and ALR2 inhibitors have been recently developed but their potential towards α-amylase inhibition remained unexplored to date. In this context, a series of novel small molecule benzo[b]thiophene-2-carboxylic acid
苯并[b]噻吩已被认为是针对广谱生物靶标的药物发现中的分子框架。在抗糖尿病药物方案中,最近开发了基于苯并[b]噻吩的 SGLT2 和 ALR2 抑制剂,但迄今为止,它们抑制 α-淀粉酶的潜力尚未被探索。在此背景下,合成、表征了一系列新型小分子苯并[b]噻吩-2-羧酸衍生物(3a-p),并评估了其作为α-淀粉酶抑制剂的抗糖尿病活性。我们发现,所有苯并[b]噻吩衍生物均表现出显着的α-淀粉酶抑制作用,IC50值范围为5.37±0.25μM至29.89±0.68μM。 SAR 研究表明,与标准药物阿卡波糖 (IC50 = 6.40 ± 0.14 μM) 相比,带有双(2-羟乙基)氨基的苯并[b]噻吩羧酸酯 (3b) 最为有效,IC50 为 5.37 ± 0.25 μM。进一步,酶抑制机制研究将3b视为α-淀粉酶的竞争性抑制剂,Ki值为1.76 μM。还进行了详细的计算机研究,以估计这些药物的结合